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Background
Development of an effective vaccine against HIV-1 is chal-
lenging due to various viral evolutionary mechanisms to
evade human immune system. The partial efficacy of the
recent RV144 vaccine efficacy trial in Thailand provides
hope for improvements of vaccine regimens for higher
efficacy. A Phase IIb proof-of-concept clinical trial in the
Republic of South Africa (RSA) is planned to confirm and
extend the results of the RV144 trial with the vaccine
strategy of poxvirus vector prime plus envelope protein
boost.
Methods
We selected two HIV subtype C gp120 vaccine antigens,
TV1.C gp120 and 1086.C gp120, formulated with Novartis
proprietary adjuvant, MF59 as protein boosts of the clini-
cal trial.
Results
To produce TV1.C gp120 and 1086.C gp120 monomers,
we generated CHO stable cell lines for both gp120, which
consistently expressed gp120 subunits with high yield.
Simple, scalable and robust antigen purification processes
were developed to generate both gp120 proteins. The ion-
exchange based purification strategy enabled the separa-
tion of gp120 monomer from dimer and produced gp120
monomer with high purity and homogeneity.
Conclusion
Purified gp120 monomers were stable, either alone or in
combination, and when formulated with adjuvant MF59.
Finally, the early evaluations showed that both gp120
monomers were immunogenic and able to elicit high
neutralizing antibody titer.
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